GH Research PLC
Business
GH Research PLC is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies for psychiatric and neurological disorders, with an initial focus on treatment-resistant depression (TRD). It develops two proprietary product candidates: GH001, an inhalable mebufotenin formulation with an associated aerosol delivery device, and GH002, an intravenous mebufotenin formulation. Its operations are organized around research and development, clinical trials, device development and regulatory interactions. The company conducts clinical programs and supplies through contract development and manufacturing organizations and targets patients and healthcare providers in the United States and Europe.
Summary from filing dated 2025-02-27
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-48.26M |
| Total assets | $288.23M |
| Total liabilities | $8.53M |
| Stockholders' equity | — |
| Operating cash flow | — |